# Industry Collaborations

- Kyle Wood MD
- Associate Professor
- Vice Chair of Research
- University of Alabama

## Disclosures – Past and Present

- Consulting and Research:
  - Novo Nordisk
  - Alnylam
  - Arbor Therapeutics
  - Biomarin
  - Chinook
  - BridgeBio

### Introduction

- Collaborations
  - Papers, Presentations, Data Collection, Research
- Challenges
  - Legal, Alignment, Time
- Intellectual Property
- Conclusion

# Collaborations

Review > J Urol. 2024 Nov;212(5):649-659. doi: 10.1097/JU.0000000000004147. Epub 2024 Aug 2.

#### The Evolving Role of Genetic Testing in Monogenic Kidney Stone Disease: Spotlight on Primary Hyperoxaluria

Matthew C Breeggemann <sup>1</sup>, Peter C Harris <sup>2</sup>, John C Lieske <sup>2</sup> <sup>3</sup>, Gregory E Tasian <sup>4</sup> <sup>5</sup>, Kyle D Wood <sup>6</sup>

> Clin J Am Soc Nephrol. 2024 Jun 1;19(6):800-802. doi: 10.2215/CJN.000000000000000460. Epub 2024 Mar 18.

#### How We Treat Primary Hyperoxaluria Type 1

Matthew C Breeggemann <sup>1</sup>, Peter C Harris <sup>2</sup>, John C Lieske <sup>2</sup> <sup>3</sup>, Gregory E Tasian <sup>4</sup> <sup>5</sup>, Kyle D Wood <sup>6</sup>

# Collaborations

> Clin J Am Soc Nephrol. 2023 Dec 1;18(12):1637-1644. doi: 10.2215/CJN.0000000000000234. Epub 2023 Jun 21.

#### End Point Considerations for Clinical Trials in Enteric Hyperoxaluria

```
Craig B Langman <sup>1</sup>, Dean Assimos <sup>2</sup>, Melanie Blank <sup>3</sup>, Juan Calle <sup>4</sup>, Andreas Grauer <sup>5</sup>, Annamaria Kausz <sup>6</sup>, Dawn Milliner <sup>7</sup>, Lama Nazzal <sup>8</sup>, Kimberly Smith <sup>9</sup>, Greg Tasian <sup>10</sup>, Aliza Thompson <sup>11</sup>, Kyle D Wood <sup>2</sup>, Elaine Worcester <sup>12</sup>, Sixun Yang <sup>13</sup>, Meaghan A Malley <sup>14</sup>, Felix Knauf <sup>15</sup>, John C Lieske <sup>7</sup> <sup>16</sup>; Rare Kidney Stone Consortium (RKSC) Kidney Health Initiative (KHI) Oxalosis and Hyperoxaluria Foundation Enteric Hyperoxaluria Workgroup (OHF EH Workgroup)
```

Observational Study > Nephrol Dial Transplant. 2024 Apr 26;39(5):788-794. doi: 10.1093/ndt/gfad221.

## Twenty-four-hour urine oxalate and risk of chronic kidney disease

```
Marja Puurunen <sup>1</sup>, Caroline Kurtz <sup>1</sup>, Alistair Wheeler <sup>1</sup>, Kyra Mulder <sup>2</sup>, Kyle Wood <sup>3</sup>, Anna Swenson <sup>2</sup>, Gary Curhan <sup>2</sup>
```

# Collaborations

> Biochim Biophys Acta Mol Basis Dis. 2019 Sep 1;1865(9):2203-2209. doi: 10.1016/j.bbadis.2019.04.017. Epub 2019 May 2.

Reduction in urinary oxalate excretion in mouse models of Primary Hyperoxaluria by RNA interference inhibition of liver lactate dehydrogenase activity

Kyle D Wood <sup>1</sup>, Ross P Holmes <sup>1</sup>, David Erbe <sup>2</sup>, Abigail Liebow <sup>2</sup>, Sonia Fargue <sup>1</sup>, John Knight <sup>1</sup>

Editorial > Clin Kidney J. 2022 May 17;15(Suppl 1):i1-i3. doi: 10.1093/ckj/sfab233. eCollection 2022 May.

Primary hyperoxaluria type 1: time for prime time?

Justine Bacchetta <sup>1</sup>, Kyle D Wood <sup>2</sup>





Legal

# Alignment





Time



# INTELLECTUAL PROPERTY DESIGN PATENTS AUTHORSHIP INVENTION COPYRIGHT PROTECTION BRAND

# Intellectual Property

